All Posts
RCT | Dipeptidyl peptidase-1 inhibition does not improve outcomes in patients hospitalized with COVID-19.
13 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
NEW Research—Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with #COVID19
Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST
From @profjdchalmers, @keirholly, @meretelong & colleagueshttps://t.co/Vlqhfs6qtj pic.twitter.com/5CY0LS4Bvy
— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022
Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts.
13 Sep, 2022 | 13:13h | UTC
Commentary on Twitter
Artificial liver support
🟤 albumin dialysis
🟤 acute failure
🟤 decompensated cirrhosis/acute‑on‑chronic failure
🟤 refractory pruritus
🟤 hypoxic injury
🟤 post‑hepatectomy failure
🟤 graft failure post #Tx
🟤 drug overdose
🟤 technique/safety#FOAMcc
📎 https://t.co/d841FcTHEd pic.twitter.com/gO79gLs60a— Intensive Care Medicine (@yourICM) September 7, 2022
AGA Clinical practice update on the endoscopic approach to recurrent acute and chronic pancreatitis.
13 Sep, 2022 | 13:12h | UTC
Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.
13 Sep, 2022 | 13:11h | UTCNeoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network
Commentary on Twitter
A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #ESMO22 https://t.co/NbICkb5kLM pic.twitter.com/a67fgxKBLy
— NEJM (@NEJM) September 12, 2022
Cohort Study | Incidence, timing, and causes of late bleeding after TAVR.
13 Sep, 2022 | 13:10h | UTCIncidence, Timing, and Causes of Late Bleeding After TAVR in an Asian Cohort – JACC: Asia
Editorial: Late Bleeding Following TAVR in Japan: An Important Cause of Mortality – JACC: Asia
Commentary: Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI – TCTMD
Retrospective Cohort Study | Outcomes of partial oral antibiotic treatment for complicated S. aureus bacteremia in people who inject drugs.
13 Sep, 2022 | 13:09h | UTCOutcomes of Partial Oral Antibiotic Treatment for Complicated S. aureus Bacteremia in People Who Inject Drugs – Clinical Infectious Diseases (free PDF for a limited period)
Commentaries on Twitter
Interesting cohort study from @WashUID led by @LauraMarks5: IV–>PO antibiotics for PWID with Staph bacteremia associated with comparable outcomes to "standard of care" all IV, esp after 10 days of IV. Don't d/c all abx at time of discharge! @CIDJournal https://t.co/0rOfYSTnkH pic.twitter.com/yqCjifWAEK
— Paul Sax (@PaulSaxMD) September 6, 2022
🆕⚡⚡#CID @LauraMarks5
PWID w comp SA bacteremia who received oral antibiotics after an incomplete IV antibiotic(~10d) were significantly less likely to experience microbiologic failure or death than pts discharged without oral antibiotics #IDTwitter https://t.co/5zXeNfx2YL pic.twitter.com/hVhFD4iJik— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 2, 2022
Review | Acute pancreatitis: diagnosis and treatment.
13 Sep, 2022 | 13:04h | UTCAcute Pancreatitis: Diagnosis and Treatment – Drugs
Commentaries:
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.
13 Sep, 2022 | 13:03h | UTCFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence
Phase 2b RCT | ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis.
13 Sep, 2022 | 13:01h | UTCABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with moderate-to-severe #ulcerativecolitis who had not responded or were intolerant to previous treatment, all three doses of obefazimod (ABX464) resulted in significantly greater reductions from baseline in modified Mayo score by week 8 vs placebo #gitwitter #IBD https://t.co/oDcQaEFVKp
— Rob Brierley (@Rob__Brierley) September 6, 2022
Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study.
13 Sep, 2022 | 13:02h | UTCRelated study: Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
M-A of randomized trials | High-flow nasal cannula oxygen therapy vs. non-invasive ventilation for patients with acute exacerbation of COPD after extubation.
13 Sep, 2022 | 13:00h | UTC
RCT | Sulopenem vs. Ciprofloxacin for the treatment of uncomplicated urinary tract infections in women.
13 Sep, 2022 | 13:00h | UTC
Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.
13 Sep, 2022 | 12:59h | UTCCommentaries:
CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)
CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)
Commentary on Twitter
NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV
— The Lancet Haematology (@TheLancetHaem) September 8, 2022
Systematic Review | Listening to music for insomnia in adults.
13 Sep, 2022 | 12:55h | UTCListening to music for insomnia in adults – Cochrane Library
Systematic Review | Adding rapid diagnostic tests to community‐based programs for treating malaria.
13 Sep, 2022 | 12:57h | UTCAdding rapid diagnostic tests to community‐based programmes for treating malaria – Cochrane Library
Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
13 Sep, 2022 | 12:56h | UTCRelated Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine
Practical Recommendations | How to deal with sleep problems during heat waves.
11 Sep, 2022 | 23:00h | UTCCommentary: How to sleep in a heat wave, according to experts – CNN
RCT | In patients with severe burns, supplemental glutamine did not improve outcomes.
11 Sep, 2022 | 22:59h | UTCA Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
RE-ENERGIZE Study: In this trial involving critically ill patients with burn injuries, enteral glutamine supplementation did not reduce the time to discharge alive from the hospital. @DarenHeyland #europeanburnsassociation #eba #burns https://t.co/f69MDVmsNv pic.twitter.com/fMWr675aCJ
— NEJM (@NEJM) September 9, 2022
RCT | In youths with new-onset type 1 diabetes, intensive glucose control for 24 months with a closed-loop system did not help to preserve pancreatic function.
11 Sep, 2022 | 22:57h | UTCClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Preservation of C-Peptide Secretion Examined in Youth With T1D – HealthDay
Commentary on Twitter (video summary)
In patients with newly diagnosed type 1 diabetes, it is uncertain whether intensive glucose control can prevent the decline in endogenous insulin secretion. New research findings are summarized in a short video. https://t.co/gJeYus4G5z pic.twitter.com/igclSnyanu
— NEJM (@NEJM) September 10, 2022
Two large clinical trials showed Vitamin D supplements do not reduce the risk of Covid-19.
11 Sep, 2022 | 22:56h | UTCEditorial: Can vitamin D protect against covid-19? – The BMJ
News Release: No link between vitamin D supplements and reduced risk of covid-19 – BMJ Newsroom
Cohort study showed a possible link between artificial sweeteners and heart disease.
11 Sep, 2022 | 22:55h | UTCNews Release: Possible link between artificial sweeteners and heart disease – BMJ Newsroom
Original Study: Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort – The BMJ
Monkeypox: disease epidemiology, host immunity and clinical interventions.
11 Sep, 2022 | 22:54h | UTC
Commentary on Twitter
Monkeypox: disease epidemiology, host immunity and clinical interventions https://t.co/dmu06NZoPt pic.twitter.com/vZqbxp7Wzn
— Nature Rev Immunol (@NatRevImmunol) September 8, 2022
Extracorporeal membrane oxygenation during respiratory pandemics: past, present, and future.
11 Sep, 2022 | 22:53h | UTC
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
11 Sep, 2022 | 22:50h | UTCAASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology
Guideline | Perioperative care of patients undergoing major complex spinal instrumentation surgery.
11 Sep, 2022 | 22:49h | UTC